Keith Alan Charlton

This inventor holds 10 USPTO granted patents and 5 published patent applications, plus 3 CIPO patents and 2 EPO patents. Top assignees: In3bio Ltd., Haptogen Ltd., Bioven 3 Limited. Active years: 2010-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Keith Alan Charlton. Retrieved from https://idiyas.com/inventor/keith-alan-charlton

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 10 (Patent Applications = 5)

% Patents Active = 90.0

CIPO Patents = 3 (Patent Applications = 2)

EPO Patents = 2 (Patent Applications = 7)

Average Co-Inventor Count = 2.2

ph-index = 2

Forward Citations = 11(Granted Patents)

Company Filing History:

Years Active: 2010-2026

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12570708 - RECOMBINANT PROTEINS AND THEIR THERAPEUTIC USES (2026-03-10),

2. 12433939 - Self-assembling synthetic proteins comprising cholera toxin beta subunit (2025-10-07),

3. 12134662 - Synthetic proteins and therapeutic uses thereof (2024-11-05),

4. 12030920 - Recombinant proteins and their therapeutic uses (2024-07-09),

5. 11419923 - Self-assembling synthetic proteins (2022-08-23),

6. 11198716 - Recombinant proteins and their therapeutic uses (2021-12-14),

7. 10736948 - Epidermal growth factor fusion proteins with mutant cholera toxin B subunits (2020-08-11),

8. 9902760 - Recombinant proteins and their therapeutic uses (2018-02-27),

9. 8168397 - Methods for the treatment of an infectious bacterial disease with an anti-lactone or lactone derived signal molecules antibody (2012-05-01),

10. 7812134 - Methods for the treatment of an infectious bacterial disease with an anti-lactone or lactone derived signal molecules antibody (2010-10-12),

Title: Keith Alan Charlton: Innovator in Synthetic Proteins

Introduction

Keith Alan Charlton is a prominent inventor based in Aberdeen, GB, known for his significant contributions to the field of synthetic proteins. With a total of 10 patents, Charlton has made remarkable strides in developing immunogenic proteins that enhance immune responses in mammals.

Latest Patents

Charlton's latest patents include groundbreaking work on self-assembling synthetic proteins comprising cholera toxin beta subunit. This innovative approach provides a synthetic immunogenic protein designed to act as an immuno-modulatory agent. It aims to enhance mammalian immune reactions towards conjugated proteins or peptides that are typically poorly immunogenic, including self-antigens. The chimeric immunogenic proteins developed in this patent can be utilized in treating various illnesses, such as cancers, infectious diseases, autoimmune diseases, allergies, and any clinical indications influenced by the immune response of a mammalian host. Another notable patent focuses on synthetic proteins and their therapeutic uses, particularly in cancer treatment.

Career Highlights

Throughout his career, Charlton has worked with notable companies, including In3bio Ltd. and Haptogen Ltd. His work has significantly impacted the development of synthetic proteins and their applications in medicine.

Collaborations

Charlton has collaborated with esteemed colleagues, including Erik D'Hondt and Daniel T Verhamme, contributing to the advancement of research in synthetic proteins.

Conclusion

Keith Alan Charlton's innovative work in synthetic proteins has the potential to revolutionize treatments for various diseases. His contributions to immunology and therapeutic applications underscore his importance as an inventor in the field.

Profile summary based on public USPTO records.